|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:approvedBy
|
1977
|
|
gptkbp:ATCCode
|
N05BA06
|
|
gptkbp:availableOn
|
gptkb:tablet
solution for injection
oral concentrate
|
|
gptkbp:brand
|
gptkb:Ativan
|
|
gptkbp:CASNumber
|
846-49-1
|
|
gptkbp:chemicalFormula
|
C15H10Cl2N2O2
|
|
gptkbp:contraindication
|
acute narrow-angle glaucoma
hypersensitivity to benzodiazepines
|
|
gptkbp:discoveredBy
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
10-20 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lorazepam
|
|
gptkbp:KEGGID
|
D08169
|
|
gptkbp:legalStatus
|
Schedule IV (US)
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:MedlinePlusID
|
a682053
a682279
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
321.16 g/mol
|
|
gptkbp:overdoseTreatment
|
gptkb:flumazenil
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:PubChem_CID
|
3819
3958
CHEMBL27
DB00186
|
|
gptkbp:riskFactor
|
abuse
memory impairment
withdrawal symptoms
paradoxical reactions
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
confusion
dizziness
drowsiness
respiratory depression
weakness
dependence
|
|
gptkbp:synonym
|
gptkb:Loramet
gptkb:Temesta
|
|
gptkbp:UNII
|
O26FZP769L
|
|
gptkbp:usedFor
|
status epilepticus
insomnia
anxiety disorders
alcohol withdrawal
preoperative sedation
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV
gptkb:Benzodiazepines
|
|
gptkbp:bfsLayer
|
6
|